Roche receives FDA clearance for Alzheimer’s blood test

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00
(photo courtesy Roche Diagnostics)

Switzerland-based Roche this week said it has received U.S. regulatory clearance for an Alzheimer’s blood test. This test is used in primary care offices for a patient’s initial assessment of Alzheimer’s disease and other causes of cognitive decline in patients 55 and older with signs or symptoms.

The Elecsys pTau 181 test—developed in collaboration with Eli Lilly and Co.—does not diagnose Alzheimer’s but instead is designed to rule out the presence of Alzheimer’s pathology early on, or indicate further diagnostics are needed.

Roche said the test, expected to be available by the end of the year, should be interpreted by health care providers in conjunction with other clinical information.

With the clearance from the U.S. Food and Drug Administration, or FDA, Indianapolis-based Roche Diagnostics will handle the marketing and distribution of the test in the United States. The test is manufactured in Germany.

The test measures phosphorylated Tau, or pTau, 181 protein found in plasma—a key biomarker for Alzheimer’s pathology including amyloid plaque and tau aggregate pathology.

Laura Parnas

“It is intended to be used as the primary care as a tool for ruling out Alzheimer’s pathology as a cause of the cognitive symptoms that patients may be presented with,” said Laura Parnas, director of medical and scientific affairs at Roche Diagnostics.

The test is useful because patients may seek care from a physician for cognitive issues for many reasons, including forgetfulness and family concerns, she said. What’s more, multiple factors such as vitamin deficiencies and sleep apnea can contribute to cognitive impairment.

“It could be due to Alzheimer’s disease as well,” Parnas said, adding it’s “another tool in the toolbox to figure out what are the causes of this cognitive decline. If this test is negative, then you focus on other things.”

Roche developed the Elecsys pTau 181 test in collaboration with Indianapolis-based Eli Lilly and Co., which has also received FDA approval for its drug, Kisunla (donanemab-azbt), to treat early symptomatic Alzheimer’s disease.

“Lilly was proud to collaborate with Roche Diagnostics on the development of this test, which is the only blood-based biomarker test available with an intended use to rule out amyloid pathology,” Lilly spokesperson Tammy McGuire said in a written statement. “It can be used in a primary care setting, which further advances the ability of those healthcare professionals to engage in the early assessment of symptomatic AD.”

In announcing the test, Roche said 92% of patients with mild cognitive impairment (early-stage symptomatic disease) go undiagnosed, so they are unable to explore whether therapeutic intervention is possible.

Having the test available in primary care settings can help significantly broaden patient access, Roche said.

The company said more than 4,500 Roche instruments are installed in clinical laboratories across the United States to integrate the Elecsys pTau181 test rapidly.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In